Not long ago, the news that #4-year-olds were worried about depression at home brought depression back into the spotlight, as a chronic, recurrent and potentially life-threatening psychiatric disorder characterized by persistent depression, pessimism, cognitive and emotional regulation disorders, sleep disorders, loss of appetite, social phobia, and unexplained physical pain
.
At present, depression in China has nearly 100 million people, and the incidence is still rising, especially among adolescents, which requires more attention
.
In recent years, with the deepening of people's understanding of depression and the strengthening of attention to mental health, patients' willingness to seek medical treatment has also increased, driving the continuous growth
of the domestic antidepressant market.
According to Intranet data, in 2021, the sales of terminal antidepressants in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) exceeded 8.
7 billion yuan, down 0.
95%
year-on-year.
Frost & Sullivan has predicted that in the next five years, the market size of the sample hospitals in China's antidepressant drug industry will continue to grow at a compound annual growth rate of 12.
7%, and will exceed 18.
4 billion yuan
by the end of 2022.
In the face of the blue ocean of the 10 billion market, not only multinational pharmaceutical companies, in recent years, local pharmaceutical companies have also increased their layout on this track, and research and development progress has continued, and in the future, domestic pharmaceutical companies may share the market cake
with imported manufacturers.
For example, on September 21, Fuyuan Pharmaceutical issued an announcement that the company's paroxetine hydrochloride enteric-coated extended-release tablets were approved by the Food and Drug Administration for production, and Fuyuan Pharmaceutical also became the third domestic enterprise to have the production of the drug, and will seize market share
with the original GlaxoSmithKline.
GlaxoSmithKline's earnings report shows that the drug's global sales in 2021 are $152 million
.
In August, Poinsettia announced that its wholly-owned subsidiary, Guangzhou Poinsettia Pharmaceutical Co.
, Ltd.
, recently received the "Drug Registration Certificate", and the vinlafaxine hydrochloride extended-release capsules were approved for listing
.
It can be used to treat depression (including depression with anxiety) and generalized anxiety disorder, and is the first-line treatment recommended by the guidelines for the diagnosis and treatment of depression and generalized anxiety disorder in many countries
.
According to data from the Intranet Network, the sales of the drug in China in 2021 have exceeded 1.
2 billion yuan.
In addition, a large number of domestic drugs are in the clinical trial or application for listing stage, among which the class 1 chemical new drug Ansulfaxin hydrochloride extended-release tablets independently developed by Luye Pharmaceutical Group have submitted a marketing application on June 11, 2021, which is suitable for major depressive disorder
.
The drug is a triple reuptake inhibitor (SNDRIs) belonging to potential serotonin (5-HT), norepinephrine (NE) and dopamine (DA), and a new molecular entity therapy with a new mechanism of action, which is expected to improve the shortcomings of the
marketed antidepressants such as slow onset and ineffective cognitive improvement.
The national class 1 new drug independently developed by Dongguang Pharmaceutical is already in clinical stage III, which is a new generation, oral, highly specific small molecule serotonin (5-HT) transporter inhibitor and 5-HT1A receptor partial agonist, with dual activity
.
In addition, on the track of clinical phase II and phase I, it also includes amoxetine hydrochloride of CSPC Pharmaceutical Group, GW-117 of widely known pharmaceuticals, JJH-201501 of Gebel Pharmaceutical, and hydroxypiridone hydrochloride of Huahai Pharmaceutical
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize:"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];
